MDXG (US)


December 16, 2025

Skin Substitute Coverage: Pyrrhic Victory?

By John Leppard

While an improvement from the skin substitute coverage policies that have been delayed since Nov. 2024, CMS’s updated intentions risk prolonging uncertainty for the likes of CTEC.LN, MDXG, and ORGO, as well as benefits for…

Read More >>

November 3, 2025

[MDXG, CTEC.LN, COLOB.C] Skin Substitute Rates & Additional Risks

By John Leppard

Consistent with our expectations, we view MDXG and CTEC.LN as most exposed to CMS’s finalized Physician Fee Schedule (PFS) policy to reduce skin substitute payments from current Average Sales Price (ASP) / invoice levels to…

Read More >>

July 15, 2025

Skin Substitutes: When it Rains it Pours [MDXG, ORGO, CTEC.LN, COLOB.DC]

By John Leppard

We view MDXG and ORGO as most negatively exposed to CMS’s proposed skin substitute policy issued last night, which would pay physicians a flat $125 / cm2 rather than product-specific rates based on Average Sales…

Read More >>

November 14, 2024

Skin Substitutes: Relief for COLOB.DC, Headiwnds for CTEC.LN & ORGO

By John Leppard

Key Takeaways: The coordinated release of finalized skin substitute local coverage determinations (LCDs) from all seven Medicare Administrative Contractors (MACs) this morning is largely in keeping with our expectations, with Coloplast (COLOB.DC) seeing the greatest…

Read More >>